gland pharma glp-1 capacity A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes drugs The $100 Billion Weight Loss

Pharmaceutical companies have invested heavily in improving injection devices to enhance patient convenience and adherence

Weight loss Clinical trials show an average 15 to 22% reduction in body weight, outperforming semaglutides 10 to 15%

[1] One study found that vegans showed no signs of carnitine deficiency

Semaglutides trade-offs are cost, gastrointestinal side effects, contraindications including medullary thyroid carcinoma history, and the need for careful titration

GLP1/E ameliorates also ovarian cyclicity in an ovulatory model of PCOS, without direct estrogenic uterotrophic effects

Envo GRATIS Este producto no se puede mezclar en la misma compra